Press Releases

Stay informed on the latest clinical milestones and scientific findings from the SABRE project as we advance bone mineral density as a regulatory endpoint for osteoporosis research.

December 15, 2025

Food and Drug Administration:
FDA Qualifies Total Hip Bone Mineral Density (BMD) as Surrogate Endpoint for Osteoporosis Drug Development

In a landmark decision for osteoporosis research, the FDA has qualified change in total hip BMD as a surrogate endpoint for fracture, significantly streamlining future clinical trials.

Read full release

December 19, 2025

Foundation for the National Institutes of Health:
FNIH Announces FDA Qualification of First Surrogate Endpoint for Use in Osteoporosis Clinical Trials

Read full release

December 19, 2025

The American Society for Bone & Mineral Research:
FDA Qualifies First Surrogate Endpoint for Use in Osteoporosis Clinical Trials

Read full release

December 22, 2025

Beth Israel Deaconess Medical Center:
BIDMC Investigator Contributes to FDA Approval of New and Better Way to Test Osteoporosis Treatments

Read full release

December 22, 2025

University of Sheffield:
Breakthrough set to accelerate osteoporosis drug development

Read full release

December 23, 2025

Entera Bio:
Entera Bio Congratulates the FNIH-ASBMR-SABRE Team on FDA’s Qualification of Total Hip BMD as Regulatory Endpoint: Huge Win for Osteoporosis Innovation

Read full release

February 20, 2026

Hospital Healthcare Europe:
Recognising a new surrogate endpoint for osteoporosis trials: the SABRE project

Read full release

Press Releases

Food and Drug Administration: FDA Qualifies Total Hip Bone Mineral Density (BMD) as Surrogate Endpoint for Osteoporosis Drug Development

Foundation for the National Institutes of Health: FNIH Announces FDA Qualification of First Surrogate Endpoint for Use in Osteoporosis Clinical Trials

The American Society for Bone & Mineral Research: FDA Qualifies First Surrogate Endpoint for Use in Osteoporosis Clinical Trials

Beth Israel Deaconess Medical Center: BIDMC Investigator Contributes to FDA Approval of New and Better Way to Test Osteoporosis Treatments

University of Sheffield: Breakthrough set to accelerate osteoporosis drug development

Entera Bio: Entera Bio Congratulates the FNIH-ASBMR-SABRE Team on FDA’s Qualification of Total Hip BMD as Regulatory Endpoint: Huge Win for Osteoporosis Innovation

Hospital Healthcare Europe: Recognising a new surrogate endpoint for osteoporosis trials: the SABRE project

Food and Drug Administration:
FDA Qualifies Total Hip Bone Mineral Density (BMD) as Surrogate Endpoint for Osteoporosis Drug Development

Foundation for the National Institutes of Health:
FNIH Announces FDA Qualification of First Surrogate Endpoint for Use in Osteoporosis Clinical Trials

The American Society for Bone & Mineral Research:
FDA Qualifies First Surrogate Endpoint for Use in Osteoporosis Clinical Trials

Beth Israel Deaconess Medical Center:
BIDMC Investigator Contributes to FDA Approval of New and Better Way to Test Osteoporosis Treatments

University of Sheffield:
Breakthrough set to accelerate osteoporosis drug development

Entera Bio:
Entera Bio Congratulates the FNIH-ASBMR-SABRE Team on FDA’s Qualification of Total Hip BMD as Regulatory Endpoint: Huge Win for Osteoporosis Innovation

Hospital Healthcare Europe:
Recognising a new surrogate endpoint for osteoporosis trials: the SABRE project